Fintech PR
Fundnel Unveils Sustained Demand for ECF Deals Amidst Global Economic Headwinds and Reports Growing Interest in Revenue-Sharing
Fundnel Malaysia today announced its performance for 2019, signalling sustained demand for alternative investments and lending. Over 240 Small and Medium-sized Enterprises (SMEs) sought the private investment platform’s expertise for fundraising, surpassing the industry’s average deal activity; four fulfilled Fundnel’s stringent requirements and have collectively raised RM5m. Across its five country markets, Fundnel secured US$120 million in essential funding for startups, private companies and venture capital funds, rendering 2019 its best year yet.
These fundraisers hail from various industries, from Food and Beverage (F&B) to Fintech. Amongst them, two SMEs — Celmonze The Signature, a one-stop beauty heaven with result-oriented face and body treatments, and CapBay, a multi-bank Supply Chain and Peer-to-Peer financing platform — were able to tap on the Malaysia Co-Investment Fund scheme by the Securities Commission Malaysia, which provided an additional boost for the businesses to pursue their next stage of growth. Majority of the funds raised were channelled to operating expenses for expansion and technology development.
Building Next-generation Private Capital Markets
Wan Mohd Firdaus, Country Director of Fundnel Malaysia, who is humbled by the ability to lend a hand to local SMEs, said, “the ultimate goal of most businesses is to generate profits. What sets exceptional businesses apart from the others is a desire to fulfil altruistic pursuits, such as a commitment to zero carbon emission or inclusive hiring.”
Fundnel is making strides toward its vision: building next-generation capital markets to enable the efficient distribution of capital that will create jobs, spur economic growth and build nations. “When we witness our work with these SMEs manifest itself in the form of new outlets, which provide gainful employment for Malaysians, or improved products or systems for the betterment of society, we are inspired to devise creative ways to reach more entrepreneurs and private companies”, he added.
Revenue-sharing: New Use Cases for a Proven Structure
In 2016, Fundnel introduced a revenue-sharing deal structure that allows a business to receive non-dilutive funding from a group of investors. In return, the business would share a part of its revenue with these investors for a fixed period of time until the principal and investment multiple has been paid up. In 2019, after years of research and implementation with numerous investors and fundraisers in the region, Fundnel officially debuted its revenue-sharing product in Malaysia.
Revenue-sharing offers a new realm of opportunities for investors. It paves the way for an investor to support a brand that resonates with personal values while providing a clear pathway for an exit within 12-24 months. Union Roastery, a speciality coffee roaster and cafe, was the first in Malaysia to raise funds through revenue-sharing from 15 individual and corporate investors, all of whom have received their principal investment along with above-expected returns. The F&B chain is currently raising a second campaign with Fundnel.
The Next Chapter for Southeast Asia’s Largest Private Investment Platform
Fundnel has five other SMEs in its pipeline that seek to launch fundraising campaigns in the weeks ahead. From evaluation to pre-launch preparation, the team was able to lay the groundwork for these deals despite the country’s movement control order — a testament to Fundnel’s digital-first approach to alternative investments and lending.
These SMEs span various industries and will be offered to investors in an array of structures. Companies of note include Enya, a digital period care company with a vision to provide affordable organic options to women; and Morganfield’s, an award-winning American-style diner with outlets across Malaysia, Singapore and Shanghai, China. Through an industry-agnostic approach and bespoke deal structuring, Fundnel ensures that it fulfils varied investor preferences while balancing the requirements of fundraisers.
In 2020, Fundnel will continue to enhance its platform to serve more Malaysian SMEs and help investors find and support everyday companies and essential services with growth potential that they care about.
Disclaimer:
Any fundraising campaign by Fundnel, including such revenue-sharing offers, are subject to its respective terms, conditions, and risks. There can be no assurance that any target rates of return will be achieved with respect to any of the fundraising campaigns, and actual results or performance of a future fundraising campaign may differ materially from the Union Roastery campaign. This press release has not been reviewed by the Securities Commission Malaysia.
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Fintech6 days agoHow to identify authenticity in crypto influencer channels
-
Latest News6 days ago
HSBC-backed fintech Monese is considering splitting its operations as it grapples with increasing losses.
-
Latest News6 days ago
EverBank has announced a groundbreaking partnership with Finzly, poised to revolutionize payment processing.
-
Latest News6 days ago
FinTech leaders express caution regarding the promises made in #Budget2024 concerning open banking, stating that the “devil is in the details.”
-
Latest News5 days ago
Gotion High-tech’s operating profit up 391% in 2023, nearly RMB 2.8 billion invested in R&D for the year
-
Latest News5 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
-
Latest News6 days ago
Wells Fargo, a leading financial institution, is set to revolutionize its trade finance operations by incorporating artificial intelligence (AI) technology through its collaboration with TradeSun.
-
Latest News5 days ago
Latvian Fintech inGain Raises €650,000 for No-Code SaaS Loan Management System